Hu Yanming, Zhou Jing, Ling Xinru, Zhao Kun, Huang Peng, Gao Max, Li Xiaoqing, Sun Ming, Zou Yanfen, Feng Guannan
Suzhou Cancer Center Core Laboratory, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Suzhou, China.
Department of Oncology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, Jiangsu, China.
Cancer Med. 2025 Apr;14(7):e70731. doi: 10.1002/cam4.70731.
Abnormal protein localization due to disrupted nucleoplasmic transport is common in tumor cells, but its mechanisms are not well understood. Nuclear pore complexes and nuclear transporter proteins are crucial for protein transport between the nucleus and cytoplasm. Evidence increasingly shows that abnormal expression of karyopherin family proteins disrupts protein translocation, affecting processes like cell differentiation, proliferation, apoptosis, and transcriptional regulation. However, their functions and roles in ovarian cancer remain unclear.
The expression level of KPNA5 in ovarian cancer tissues and cells was detected by IHC, Western blot, and qPCR. CCK-8 and colony formation assays were used to assess cell proliferation ability. Transwell assay was conducted to determine cell migration and invasion capacity. A xenograft model was used to assess the effect of KPNA5 on tumor growth in vivo.
KPNA5 expression is downregulated in ovarian cancer (OC) tissues. Low KPNA5 levels were associated with poor survival in OC patients, validated by an OC tissue sample cohort. Overexpression of KPNA5 significantly suppressed OC cell proliferation, tumor growth, and invasion in both in vitro and in vivo studies. Mechanistically, KPNA5 recognizes nuclear localization signals (NLSs) in PTPN4, mediating its nuclear transport and inhibiting STAT3 phosphorylation and its downstream signaling pathway. Similarly, PTPN4 overexpression reduced OC cell viability and invasion, also suppressing STAT3 phosphorylation.
Our findings identify KPNA5 as a tumor suppressor in OC, presenting a potential therapeutic target for OC treatment.
由于核质运输受阻导致的蛋白质定位异常在肿瘤细胞中很常见,但其机制尚不清楚。核孔复合体和核转运蛋白对于细胞核与细胞质之间的蛋白质运输至关重要。越来越多的证据表明,核转运蛋白家族蛋白的异常表达会破坏蛋白质转运,影响细胞分化、增殖、凋亡和转录调控等过程。然而,它们在卵巢癌中的功能和作用仍不清楚。
采用免疫组化、蛋白质免疫印迹法和定量聚合酶链反应检测卵巢癌组织和细胞中KPNA5的表达水平。采用细胞计数试剂盒-8法和集落形成试验评估细胞增殖能力。进行Transwell试验以确定细胞迁移和侵袭能力。采用异种移植模型评估KPNA5对体内肿瘤生长的影响。
卵巢癌(OC)组织中KPNA5表达下调。OC患者低KPNA5水平与较差的生存率相关,这在一组OC组织样本中得到验证。在体外和体内研究中,KPNA5的过表达均显著抑制OC细胞增殖、肿瘤生长和侵袭。机制上,KPNA5识别PTPN4中的核定位信号(NLS),介导其核运输并抑制STAT3磷酸化及其下游信号通路。同样,PTPN4的过表达降低了OC细胞的活力和侵袭能力,也抑制了STAT3磷酸化。
我们的研究结果确定KPNA5为OC中的一种肿瘤抑制因子,为OC治疗提供了一个潜在的治疗靶点。